GlassScriptPhysician profile
Benjamin S Rudnitsky
NPI 1619958113
$3,108.53
in general payments reported to CMS, 2019-2025
29 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $93.06 · 2021: $221 · 2022: $354 · 2023: $581 · 2024: $798 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,913 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,913.16 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $350.95 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Astrazeneca Pharmaceuticals LP | $322.46 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $259.63 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $196.25 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $163.57 | 2019-2025 | Velphoro |
| Opko Pharmaceuticals, LLC | $150.52 | 2019-2024 | Rayaldee |
| Novo Nordisk INC | $146.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $144.31 | 2021-2022 | |
| Glaxosmithkline, LLC. | $137.99 | 2022-2025 | Benlysta, Jesduvroq |
| Horizon Therapeutics Plc | $136.02 | 2022-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $129.56 | 2021-2025 | |
| Vifor Pharma, INC. | $108.27 | 2019-2025 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.44 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $106.17 | 2023-2025 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $87.24 | 2023-2025 | Purified Cortrophin Gel |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $77.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $69.77 | 2025 | |
| Nxstage Medical, INC. | $65.48 | 2019 | |
| Akebia Therapeutics INC | $63.71 | 2024-2025 | Vafseo |
| Ardelyx, INC. | $49.48 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $36.82 | 2024-2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.46 | 2023-2024 | Jynarque |
| Alexion Pharmaceuticals, INC. | $35.16 | 2019 | |
| Bard Peripheral Vascular, INC. | $26.17 | 2019-2021 | |
| Daiichi Sankyo INC. | $25.12 | 2022 | |
| Aurinia Pharma U.S., INC. | $24.28 | 2024 | Lupkynis |
| Kyowa Kirin, INC. | $19.71 | 2022 | |
| Genentech USA, INC. | $18.12 | 2019 | |
| Cormedix INC. | $14.48 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Rudnitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.